Risedronate
Active ingredient: Risedronate Sodium Hemipentahydrate, Risedronate Sodium Monohydrate
In short: Risedronate sodium delayed-release is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures .
What is Risedronate used for?
Risedronate sodium delayed-release is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures .
The optimal duration of use has not been determined. The safety and effectiveness of Risedronate sodium delayed-release for the treatment of osteoporosis are based on clinical data of one year duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
Risedronate dosage
The recommended regimen is:
one 35 mg delayed-release tablet orally, taken once-a-week
Instruct patients to do the following:
Take Risedronate sodium delayed-release in the morning immediately following breakfast. Risedronate sodium delayed-release should be taken immediately following breakfast and not under fasting conditions because of a higher risk of abdominal pain if taken before breakfast when fasting.
Swallow Risedronate sodium delayed-release whole while in an upright position and with at least 4 ounces of plain water to facilitate delivery to the stomach. Avoid lying down for 30 minutes after taking the medication .
Do not chew, cut, or crush Risedronate sodium delayed-release tablets.
Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate and to take calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations at a different time of the day as they interfere with the absorption of Risedronate sodium delayed-release.
If the once-weekly dose is missed, instruct patients to take one tablet on the morning after they remember and return to taking one tablet once-a-week, as originally scheduled on their chosen day. Patients should not take two tablets on the same day.
How to take Risedronate — instructions & advice from the label
See FDA-approved patient labeling (Medication Guide)
Instruct patients to read the Medication Guide before starting therapy with Risedronate sodium delayed-release and to re-read it each time the prescription is renewed.
Instruct patients that Risedronate sodium delayed-release and Risedronate sodium immediate-release contain the same active ingredient and if they are taking Risedronate sodium immediate-release, they should not take Risedronate sodium delayed-release .
Instruct patients to pay particular attention to the dosing instructions as clinical benefits may be compromised by failure to take the drug according to instructions.
Instruct patients to take Risedronate sodium delayed-release in the morning, while in an upright position (sitting or standing) with at least 4 ounces of plain water immediately following breakfast. Risedronate sodium delayed-release should not be taken before breakfast.
Instruct patients to swallow Risedronate sodium delayed-release tablets whole. Patients should not chew, cut, or crush the tablet because of a potential for oropharyngeal irritation, and because the tablet coating is an important part of the delayed-release formulation. …
Warnings & precautions
Do not take this medicine if: Risedronate sodium delayed-release is contraindicated in patients with the following conditions:
Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
Inability to stand or sit upright for at least 30 minutes
Hypocalcemia
Known hypersensitivity to any component of this product. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported
Risedronate sodium delayed-release contains the same active ingredient found in Risedronate sodium immediate-release. A patient being treated with Risedronate sodium immediate-release should not receive Risedronate sodium delayed-release.
Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Risedronate sodium delayed-release is given to patients with active upper gastrointestinal problems (such as known Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers) [
see
Contraindications (4)
,
Adverse Reactions (6.1)
,
Information for Patients (17)
].
Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. …
Risedronate side effects
The following clinically significant adverse drug reactions are described elsewhere in the labeling:
Drug Products with the Same Active Ingredient
Upper Gastrointestinal Adverse Reactions
Mineral Metabolism
Jaw Osteonecrosis
Musculoskeletal Pain
Atypical Fractures Including Femoral Fractures
Renal Impairment
Laboratory Test Interactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Treatment of Postmenopausal Osteoporosis
Once-a-Week Dosing with
Risedronate sodium
delayed-release
tablets
The safety of Risedronate sodium delayed-release 35 mg once-a-week in the treatment of postmenopausal osteoporosis was assessed in a 1-year, double-blind, multicenter study comparing Risedronate sodium delayed-release 35 mg once-a-week to risedronate sodium immediate-release 5 mg daily in postmenopausal women 50 years of age or older. Risedronate sodium delayed-release was administered either at least 30 minutes before (N = 308) or immediately following (N = 307) breakfast, and risedronate sodium immediate-release 5 mg daily (N = 307) was administered at least 30 minutes before breakfast. …
Drug interactions
Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450).
When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% . Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together.
Drugs that raise stomach pH (for example, PPIs or H2 blockers) may cause faster drug release from enteric coated (delayed-release) drug products such as Risedronate sodium delayed-release. Co-administration of Risedronate sodium delayed-release with the PPI, esomeprazole, increased risedronate bioavailability. The maximum plasma concentration (Cmax) and the area under the plasma concentration (AUC) were increased by 60 percent and 22 percent, respectively.
Concomitant administration of Risedronate sodium delayed-release and H2 blockers or PPIs is not recommended.
Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. …
About this medicine
Risedronate sodium delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA).
Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each Risedronate sodium delayed-release tablet for oral administration contains the equivalent of 35 mg of anhydrous risedronate sodium in the form of the hemi-pentahydrate with small amounts of monohydrate. The empirical formula for risedronate sodium hemi-pentahydrate is C7H10NO7P2Na •2.5 H2O. The chemical name of risedronate sodium is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt. The chemical structure of risedronate sodium hemi-pentahydrate is the following:
Molecular Weight: Anhydrous:
305.10 Hemi-pentahydrate:
350.13
Risedronate sodium is a fine, white to off-white, odorless, crystalline powder. It is soluble in water and in aqueous solutions, and essentially insoluble in common organic solvents. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c89430be-15f1-4b8b-ab7e-738de716ee7d. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone